AustCancer Targeting European Investors through Frankfurt Exchange Xetra Listing

ASX/MEDIA RELEASE
Monday 20 September 2004

Sydney, Australia. The Board of the rapidly growing international biotechnology company, Australian Cancer Technology (“AustCancer” ASX:ACU) today announced that it has undertaken a secondary listing on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange.

AustCancer has contracted the Frankfurt based securities broker dealer firm, Seydler AG Securities and Financial Services, to act as Market Maker and Designated Sponsor for the company’s shares on Xetra.

The Xetra listing is part of AustCancer’s strategy to broaden its international shareholder base. The company already has a Level 1 ADR program on NASDAQ (Code AUCJY) and plans to complete a small cap NASDAQ listing by the third quarter of the current financial year. The German listing is particularly significant, given AustCancer’s recently announced agreement with the German company RESprotect GmbH to acquire the North American licence to the highly promising developmental pancreatic cancer drug RP101.

The code for AustCancer shares on Xetra is CBS and the German securities code (ISIN) is AU000000ACU7.

Dr Roger Aston, AustCancer Chairman said, “AustCancer is now very much an international biotechnology company with business activities in the United States, Europe, Asia and Australia and we are keen to also grow our international shareholder base. The Xetra listing gives European investors, particularly those familiar with the German pancreatic drug technology we have recently acquired, the opportunity to participate in the growth opportunities we have available to us.”

ENDS-

About Australian Cancer Technology
Listed on the Australian Stock Exchange (code: ACU) Australian Cancer Technology is a broadly based international oncology company developing a portfolio of high quality oncology-related projects that are at various stages of commercialisation. Cash generating businesses will provide the funds to exploit the potential of its leading products and to introduce promising pre-clinical and Phase I projects into the development pipeline. Its leading edge PentrysTM anti-cancer vaccine successfully completed Phase I and Phase I/IIa trials at St. Vincent’s Hospital Sydney and is undergoing a comprehensive Phase IIb trial with prostate cancer patients at three leading Melbourne institutions. Its US subsidiary, revisysTM, is launching a range of medical nutritionals designed by leading US scientists for people with special needs, including those undergoing cancer treatment. The company is also broadening its cancer therapeutic development pipeline and has acquired the US based Galenica Pharmaceuticals, whose immune enhancing adjuvants are being used in three Phase I and II cancer trials and will be used in a number of other forthcoming clinical trials in association with Memorial Sloan Kettering Cancer Centre in New York. The company has also recently announced the acquisition of the North American licence for the promising pancreatic cancer drug, RP101, for which it is developing an accelerated clinical trial program including application to the USFDA for Orphan Drug status. AustCancer has established a Level 1 ADR stock program in the US, trading under the code of AUCJY.
www.austcancer.com.au